Institutional members access full text with Ovid®

Share this article on:

AUTOSOMAL DOMINANT VITREORETINOCHOROIDOPATHY: When Molecular Genetic Testing Helps Clinical Diagnosis

Boulanger-Scemama, Elise, MD*; Sahel, Jose-Alain, MD, PhD*,†,‡,§,¶; Mohand-Said, Saddek, MD†,§; Antonio, Aline§; Condroyer, Christel§; Zeitz, Christina, PhD§; Audo, Isabelle, MD, PhD†,§,**

doi: 10.1097/IAE.0000000000002041
Original Study: PDF Only

Purpose: Autosomal dominant vitreoretinochoroidopathy is an extremely rare disease, which belongs to the BEST1-related disease spectrum.

Methods: Report of five patients with an initial diagnosis of atypical rod–cone dystrophy, for whom autosomal dominant vitreoretinochoroidopathy was retrospectively diagnosed on genetic results using targeted next-generation sequencing. Each patient had a comprehensive ophthalmic examination including multimodal retinal imaging and functional evaluation.

Results: Visual acuity ranged from <20/800 to 20/25. Two patients had narrowed angle with history of acute angle-closure glaucoma for one patient. Full-field electroretinogram showed severe reduction of both scotopic and photopic responses for 3/5 patients. Electrooculogram could be performed for one of the two patients with moderate alterations of full-field electroretinogram. It revealed severe light rise abnormalities with decreased Arden ratio (125% right eye, 145% left eye) in keeping with generalized severe dysfunction of the retinal pigment epithelium. On fundoscopy, the pathognomonic circumferential hyperpigmented band of the peripheral retina was totally absent in two patients.

Conclusion: This report highlights the high phenotypic variability of autosomal dominant vitreoretinochoroidopathy, which may be misdiagnosed, especially in advanced forms with severe generalized photoreceptor dysfunction mimicking retinitis pigmentosa. Targeted next-generation sequencing can contribute to the proper clinical diagnosis, especially in case of atypical phenotypic features of autosomal dominant vitreoretinochoroidopathy.

*Fondation Ophtalmologique Adolphe de Rothschild, Paris, France;

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, DHUSight Restore, INSERM-DGOS CIC 1423, Paris, France;

Académie des Sciences-Institut de France, Paris, France;

§Sorbonne Universités, UPMC Univ Paris 06, INSERM U968, CNRS UMR_7210, Institut de la Vision, Paris, France;

Department of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and

**Institute of Ophthalmology, University College of London, London, United Kingdom.

Reprint requests: Isabelle Audo, MD, PhD, Department of Genetics, INSERM, UMR_S968, CNRS, UMR_7210, UPMC Univ Paris 06, Institut de la Vision, 17 Rue Moreau, F-75012 Paris, France; e-mail: isabelle.audo@inserm.fr

Supported by Fondation Voir et Entendre (C. Zeitz), Prix Dalloz for “La recherche en ophtalmologie” (C. Zeitz), LABEX LIFESENSES (reference ANR-10-LABX-65) supported by French state funds managed by the Agence Nationale de la Recherche within the Investissements d'Avenir program (ANR-11-IDEX-0004-0), Foundation Fighting Blindness center grant (C-CMM-0907-0428-INSERM04), and Prix de la Fondation de l'Œil (I. Audo).

None of the authors has any conflicting interests to disclose.

© 2018 by Ophthalmic Communications Society, Inc.